共 31 条
[1]
McArdle A(2018)Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs Clin Rev Allergy Immunol 55 271-294
[2]
Pennington S(2020)Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as core instrument to measure health-related quality of life in psoriatic arthritis: a systematic review of psychometric properties J Psoriasis Psoriatic Arthritis 5 12-22
[3]
FitzGerald O(2019)The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies Ann Rheum Dis 78 1215-1219
[4]
Holland R(2020)Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey Rheumatol Ther 7 617-637
[5]
Højgaard P(2020)EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update Ann Rheum Dis 79 700-712
[6]
Tillett W(2020)A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial Ann Rheum Dis 79 123-131
[7]
Kavanaugh A(2018)Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis J Immunol 201 1605-1613
[8]
Gottlieb A(2020)Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52 Ann Rheum Dis 79 1310-1319
[9]
Morita A(2021)Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52 Clin Rheumatol 59 i21-i28
[10]
Tillett W(2020)Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management Rheumatology (Oxford) 6 e001223-undefined